新聞/Reuters/US FDA declines to approve Capricor's muscle disorder therapyUS FDA declines to approve Capricor's muscle disorder therapyRefinitiv閱讀少於1分鐘CAPRCapricor Therapeutics CAPR said on Friday the U.S. Food and Drug Administration has declined to approve its cell therapy for a type of muscle disorder.Reuters美國股票© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html顯示更多登入或建立一個永久免費帳戶來閱讀此新聞讓我們開始吧
